Abstract: In some embodiments, one general aspect includes a method of mitigating disrupted communication with an analyte sensor. The method includes receiving, at a first device, analyte measurements from the analyte sensor. The method also includes receiving, at the first device, an indication of a communication disruption between the analyte sensor and a second device. The method also includes, responsive to the indication, at the first device, facilitating transfer of at least a portion of the analyte measurements from the first device to the second device.

Abstract: In one embodiment, a method of alert optimization includes receiving, at a first device, one or more analyte measurements produced by an analyte sensor worn by a patient. The method also includes determining, at the first device, a first unique identifier for a first alert based on the one or more analyte measurements. The method also includes comparing, at the first device, the first unique identifier for the first alert to a stored record that includes unique identifiers for historical alerts. The method also includes conditionally suppressing the first alert on the first device based on the comparing.

Abstract: The present invention relates to identification of cellular components, genotypes and gene expression profiles associated with mood disorders. In some embodiments, the present invention relates to the correlation between ribosomal protein S6 (RPS6) and depression and/or anxiety. Embodiments of the present invention further relate to regulation of the activity of RPS6, e.g., by p90 Ribosomal S6 protein kinase. Embodiments of the present invention provide methods and compositions for, e.g., diagnosing, treating, and monitoring depression and/or anxiety, or risk thereof, and for selecting, monitoring, and tailoring treatments for depression and/or anxiety.